肿瘤细胞减灭术联合腹腔热灌注化疗治疗腹膜肉瘤病:机构回顾性研究
印度某三级肿瘤中心回顾性分析2014至2020年24例继发于子宫及腹膜后肉瘤的腹膜肉瘤病患者,均接受肿瘤细胞减灭术联合腹腔热灌注化疗并随访至少5年。完全细胞减灭(CC-0/1)达92%,中位总生存35个月,中位无进展生存14个月,复发率67%,术后并发症17%,无30天死亡。
要点
- 完全细胞减灭(CC-0/1)率92%,与较好生存相关
- 中位总生存35个月,5年生存率30%,复发率67%
- 术后并发症17%,无30天死亡,围术期安全性可接受
核心结论
- 肿瘤细胞减灭术联合腹腔热灌注化疗可能为选择性腹膜肉瘤病患者带来生存获益,尤其是实现完全细胞减灭者。
- 尽管复发率仍高,该方案相较单纯全身治疗可能改善结局,但需进一步前瞻性研究优化患者选择。
研究设计与样本
- 单中心回顾性分析,纳入2014至2020年印度某三级肿瘤中心24例继发于子宫和腹膜后肉瘤的腹膜肉瘤病患者。
- 患者接受肿瘤细胞减灭术联合腹腔热灌注化疗,随访至少5年;评估指标包括细胞减灭完整性(CC-0/1)、围术期并发症、总生存和无进展生存。
主要发现
- 队列包括16例子宫肉瘤和8例腹膜后肉瘤患者,完全细胞减灭(CC-0/1)达92%。
- 中位总生存35个月(子宫肉瘤32个月,腹膜后肉瘤38个月),1年、3年、5年生存率分别为75%、50%、30%。
- 中位无进展生存14个月,复发率67%;术后并发症发生率17%,无30天死亡。
临床怎么用
- 对经选择的腹膜肉瘤病患者,可考虑肿瘤细胞减灭术联合腹腔热灌注化疗,目标是实现完全细胞减灭(CC-0/1)。
- 应向患者说明复发率较高(67%),并强调该策略目前仍属争议性选择,需个体化评估。
局限性
- 回顾性单中心设计,样本量仅24例,选择偏倚难以避免,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peritoneal sarcomatosis is a rare and aggressive condition with limited treatment options. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy has been explored as a potential therapeutic strategy, although its efficacy remains uncertain. METHODS: We conducted a retrospective analysis of 24 patients with peritoneal sarcomatosis secondary to uterine and retroperitoneal sarcomas treated at a tertiary oncology center in India between 2014 and 2020. Eligible patients underwent cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, with follow-up extending for at least 5 years. Outcomes assessed included completeness of cytoreduction (CC-0/1), perioperative morbidity, overall survival, and progression-free survival. RESULTS: The cohort comprised patients with 16 uterine sarcoma and 8 patients with retroperitoneal sarcoma. Complete cytoreduction (CC-0/1) was achieved in 92% of cases. The median overall survival was 35 months (uterine: 32 months; retroperitoneal: 38 months), with 1-, 3-, and 5-year survival rates of 75%, 50%, and 30%, respectively. The median progression-free survival was 14 months, with a recurrence rate of 67%. Postoperative complications occurred in 17%, with no 30-day mortality. CONCLUSION: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy offers a potential survival benefit for select patients with peritoneal sarcomatosis, particularly those with complete cytoreduction. Although recurrence rates remain high, this approach may improve outcomes compared with systemic therapy alone. Further prospective studies are needed to refine patient selection and optimize treatment strategies.
引用
- Ray MD, Kapoor R. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis: Therapeutic advancement or clinical controversy? An institutional review. Surgery. 2025. PMID: 41138543. doi:10.1016/j.surg.2025.109828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。